

Troikaa wins award for excellence in 'research in science and technology'

Express Pharma - June 1 -15, 2010

Troikaa Pharmaceuticals has been awarded for excellence in 'Research in Science and Technology' for the year 2009 by the Federation of Gujarat Industries (FGI). Troikaa won the award for in-house research in developing the world's first painless diclofenac injection - Dynapar AQ. Dr. Montek Singh Ahluwalia, Dy. Chairman, Planning Commission, Government of India, presented the award at a function organised by FGI.

Speaking on the occasion, Ketan Patel, Managing Director, Troikaa Pharmaceuticals said, "This award recognises our sustained commitment to develop innovative drug delivery systems for patients. This is the second award conferred on the Company for the innovative product Dynapar AQ. Given our inherent focus on customer-centric innovations, hopefully there will be more recognition in the years to come."

Within two and a half years of launch, Dynapar AQ is the second largest brand of diclofenac injections in the country. The Company has been granted the patent for this product in India as well as in 29 other countries and is in the process of procuring patents in 70 other countries.

Diclofenac injections are routinely used for management of acute pain and inflammation. Dynapar AQ injections are the world's only diclofenac injections that can be administered in the arm muscles, especially useful in obese and overweight patients and those with large amount of fat on the buttocks. It is also the first diclofenac available in pre-filled syringes.

FGI presents biennial awards for excellence in economic, societal and scientific areas. This year, FGI has constituted awards for excellence in 13 categories across different fields.
